Using cold plasma to treat warts and molluscum in children and young adults
Cold Atmospheric Plasma Device for the Treatment of Molluscum Contagiosum and Verruca Vulgaris in Pediatric Patients - Open-Label Extension Study
This study is testing if a cold plasma device can help children and young adults with warts and molluscum get rid of their skin lesions.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 4 Years to 21 Years |
| Sex | All |
| Sponsor | Medical University of South Carolina Academic / other |
| Locations | 1 site (Charleston, South Carolina) |
| Trial ID | NCT05937672 on ClinicalTrials.gov |
What this trial studies
This clinical trial involves patients aged 4 to 21 years who have at least one wart or molluscum lesion. Participants will receive treatment with a cold atmospheric plasma device, which is designed to target and reduce the size and appearance of these lesions. The study will last a minimum of 4 weeks, with potential monthly treatments for up to a year, depending on the response to treatment. The effectiveness and safety of the treatment will be assessed through measurements of lesion size, pain, and appearance, along with photographic documentation and dermatologist evaluations.
Who should consider this trial
Good fit: Ideal candidates are children and young adults aged 4 to 21 with at least one wart or molluscum lesion.
Not a fit: Patients with lesions on the face or genital areas, or those with conditions leading to excessive scarring, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive option for effectively managing warts and molluscum in pediatric patients.
How similar studies have performed: While the use of cold atmospheric plasma is a novel approach, similar studies in dermatology have shown promising results in treating skin lesions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients from 4-21 years old with at least 1 lesion of vercurra or molluscum. * Willingness of the participant and their guardian to provide consent when applicable. Exclusion Criteria: * Unwillingness to participate in the study * Received any treatment on the lesion in the past month determined by review of their medical record * Immunodeficiency determined by review of their medical record. * Adverse response to prior treatments determined by review of medical record. * Signs of self-resolution determined by study team members. * Conditions that lead to excessive scarring determined by study team members. * Face and genital lesions determined by study team members.
Where this trial is running
Charleston, South Carolina
- Medical University of South Carolina — Charleston, South Carolina, United States (Recruiting)
Study contacts
- Study coordinator: Courtney Linkous, BA
- Email: linkousc@musc.edu
- Phone: 843-566-2453
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.